Contact: Dana Barocas Business Development & Marketing Manager NEVO
Europe Tel: +44-797-827-9209 Email: office@nevo-europe.
Dental assistants can do more with NEVO
, freeing up the doctor to do more production.
Business of Dentistry attendees will enjoy the first professional exhibition of the E4D NEVO
System, which is expected to begin shipping in September for customers in the U.
In the NEVO
RES I trial, patients completed the questionnaire when they were initially randomized and then one and six months after treatment.
Gary Kaye, DDS, FAGD, founder and principal dentist of New York City-based Kaye Dentistry, recently hosted a hands-on demonstration of NEVO
for leading dental professionals.
RES I was not designed to show differences in clinical outcomes, however, patients treated with NEVO
(TM) had numerically lower rates of events with respect to target lesion revascularization (1.
The E4D NEVO
Scanner and Design Center represents what we call the 'Natural EVOlution' of digital dentistry," said Mark Quadling, CEO of D4D Technologies.
While describing the goals of NEVO
thus that could avail all, combining government officials, regardless of their political gatherings, Mr.
Principal Investigator of both CYPRESS and NEVO
In the NEVO
RES 1 study, a similar magnitude of benefit of the NEVO
([TM]) Sirolimus-eluting Coronary Stent over the Taxus([R]) Liberte([R]) Stent was seen in patients with diabetes as in patients without diabetes.
In March, Cordis announced plans to initiate a new trial - called NEVO
II - which is planned as an approximately 2,000-patient, randomized, non-inferiority, head-to-head global trial comparing NEVO
([TM]) to the XIENCE([TM]) Stent.
II will be a global, randomized, non-inferiority trial of approximately 2,000 patients with coronary artery disease.